Satori Pharma Raises $22 Million
Satori Pharmaceuticals Inc., a Cambridge, Mass.-based developer of therapeutics for neurodegenerative disorders like Alzheimer's disease and Parkinson's disease, has raised $22 million in Series B funding. InterWest Partners, Prospect Venture Partners and New Enterprise Associates co-led the round, and were joined by return backers like PureTech Ventures. In other Satori news, the company named former Pfizer exec Jeffrey Ives as CEO.
8 January 2009•6 mins read
